The following is a summary of the G1 Therapeutics, Inc. (GTHX) Q4 2023 Earnings Call Transcript:

Financial Performance:

• G1 Therapeutics reported Q4 2023 revenue of $14.9 million, up 45% YoY.

• Sales from COSELA were $13.9 million and license revenue contributed $1 million.

• Total revenue for FY 2023 was $82.5 million, showing a significant growth from $51.3 million in FY 2022.

• Operating expenses decreased by 35%, and the company ended the quarter with cash, cash equivalents, and marketable securities of $82.2 million.

• Net COSELA revenue is projected to be between $60 and $70 million for 2024, with a year-end cash balance expected to range from $50 to $60 million.

Business Progress:

• G1 is expecting results from ongoing Phase 3 PRESERVE 2 trial of trilaciclib in metastatic settings by the third quarter.

• The year ahead sees promise with the use of ADCs in second line and TNBC treatment settings.

• G1's commercial team is focusing on driving COSELA penetration, aiming to reduce chemotherapy-related myelosuppressive side effects.

• The sales performance surpassed expectations, with 19% overall vial volume growth compared to Q3 2023.

• The focus remains on continued volume growth and sales, with the company adding 2 new top 100 customers in Q4.

• G1 continues advancing its clinical trials with promising initial results from the trilaciclib plus TROP2 ADC sacituzumab govitecan Phase 2 trial.

• The company is keen on extending its cash runway into 2025, despite various implementation costs, and remains proactive in identifying potential efficiency improvements.

More details: G1 Therapeutics IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.